Bridgeway Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Bridgeway Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,400	Closed	-$76.9K	–	1283
2026 Q1	$76.9K	Hold	13,400	–	–	﹤0.01%	1157
2025 Q4	$133K	Sell	13,400 -35,000	-72%	-$319K	﹤0.01%	1088
2025 Q3	$321K	Sell	48,400 -5,000	-9%	-$24.2K	0.01%	907
2025 Q2	$215K	Buy	53,400 +15,000	+39%	+$49.3K	0.01%	946
2025 Q1	$133K	Sell	38,400 -26,600	-41%	-$118K	﹤0.01%	993
2024 Q4	$428K	Buy	+65,000	New	+$512K	0.01%	849

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Bridgeway Capital Management's LXEO Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 13,400 shares — an estimated $76.9K sold.

Bridgeway Capital Management first reported a position in LXEO in Q4 2024 and held it in 6 quarters. The position peaked at $428K in Q4 2024. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Bridgeway Capital Management reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 13,400 Lexeo Therapeutics shares in Q2 2026, an estimated $76.9K.
Bridgeway Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 6 quarters.
Bridgeway Capital Management's Lexeo Therapeutics position peaked at $428K in Q4 2024.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.